Inhibitor Therapeutics (INTI) 8-K Changes in Registrant's Certifying Accountant

Exhibit 16.1

February 4, 2013

Securities and Exchange Commission

Washington, D.C. 20549

Ladies and Gentlemen:

We have reviewed the disclosures concerning Witt Mares, PLC and PBMares, LLP made by Commonwealth Biotechnologies, Inc. in Item 4.01 of its Form 8-K, which we understand will be filed with the Securities and Exchange Commission on the date hereof, and are in agreement with the statements contained therein.

Very truly yours,

/s/ Witt Mares, PLC

Witt Mares, PLC

Norfolk, Virginia